Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Survival in patients with sleep apnoea (SA) can be reduced by variables such as age, sex, and comorbidities. However, survival data in patients with SA in Colombia remains scarce.

Methods: This is a retrospective cohort study of patients diagnosed with SA between 2005 and 2022. Five-year survival was assessed using the Kaplan-Meier method, and survival curves were stratified by age, sex, and cardiovascular disease. Risk factors associated with survival were evaluated using Hazard Ratio (HR) by adjusting for confounding variables with a Cox regression model. A minimum sample size of 1537 patients were estimated to be necessary to estimate a survival incidence rate with a 5% precision.

Results: The five-year survival rate in the general population was 94.6%, with lower survival in patients over 65 years (88.5% vs 97.9%; p < 0.001) and in patients with cardiovascular disease (89% vs 95.2%; p < 0.001) compared to the control group. In the Cox regression, age showed an HR of 1.05 (95% CI: 1.02-1.07; p < 0.001). Male sex had an HR of 2.31 (95% CI: 1.25-4.25; p = 0.007), congestive heart failure an HR of 4.00 (95% CI: 2.31-6.94; p < 0.001), chronic obstructive pulmonary disease (COPD) an HR of 1.75 (95% CI: 1.04-2.96; p = 0.035), chronic kidney disease (CKD) an HR of 2.23 (95% CI: 1.31-3.78; p = 0.003), and metastatic cancer an HR of 4.96 (95% CI: 1.95-12.60; p = 0.001).

Conclusion: The study showed a high five-year survival rate in patients with SA. The risk factors associated with decreased overall five-year survival were age, male sex, cardiovascular disease, COPD, CKD, and metastatic cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470772PMC
http://dx.doi.org/10.2147/NSS.S481010DOI Listing

Publication Analysis

Top Keywords

five-year survival
16
risk factors
12
factors associated
12
cardiovascular disease
12
survival
11
patients
8
patients sleep
8
sleep apnoea
8
retrospective cohort
8
cohort study
8

Similar Publications

Objective: Thymic tumors are a rare group of anterior mediastinal tumors. Surgery is the primary treatment. Adjuvant treatment is used in select cases.

View Article and Find Full Text PDF

Introduction Breast cancer (BC) is the most common malignancy among women worldwide and the leading cause of cancer-related mortality in women in Morocco. However, there is limited evidence on survival outcomes and treatment patterns among elderly patients with metastatic breast cancer (MBC) in this setting. Methods We conducted a retrospective cohort study at the Department of Medical Oncology, Hassan II University Hospital in Fez.

View Article and Find Full Text PDF

Utilizing the Timed Up and Go Test to Predict Five-Year Mortalities Among Older Cardiovascular Inpatients: A Prospective Cohort Study.

Rev Cardiovasc Med

August 2025

Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730 Beijing, China.

Background: To examine the predictive value of the Timed Up and Go test (TUGT) for five-year mortality among older patients with cardiovascular disease (CVD).

Methods: This prospective cohort study was conducted at the Beijing Hospital in China from September 2018 to April 2019, with a follow-up period of 5 years. Patients underwent the TUGT at baseline and were categorized into two groups based on the subsequent results: Group 1 (TUGT >15 s) and Group 2 (TUGT ≤15 s).

View Article and Find Full Text PDF

Identifying ARRB2 as a Prognostic Biomarker and Key Player in the Tumor Microenvironment of Pancreatic Cancer through scPagwas Methodology.

Curr Gene Ther

September 2025

Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, Jiangsu, China.

Introduction: Pancreatic Cancer (PC) is recognized as a highly aggressive malignancy and is anticipated to become the second leading cause of cancer-associated deaths across the United States by 2030. Owing to its late-stage diagnosis and the substantial risk of metastasis, current therapeutic strategies exhibit limited efficacy, resulting in a five-year survival rate below 10%. Consequently, identifying reliable biomarkers and therapeutic approaches remains imperative for enhancing treatment effectiveness.

View Article and Find Full Text PDF

Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers.

Signal Transduct Target Ther

September 2025

State Key Laboratory of Molecular Oncology & Department of Medical Oncology & Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor strongly associated with exposure to tobacco carcinogens, is characterized by early dissemination and dismal prognosis with a five-year overall survival of less than 7%. High-frequency gain-of-function mutations in oncogenes are rarely reported, and intratumor heterogeneity (ITH) remains to be determined in SCLC. Here, via multiomics analyses of 314 SCLCs, we found that the ASCL1/MKI67 and ASCL1/CRIP2 clusters accounted for 74.

View Article and Find Full Text PDF